Advaxis Doses First Patient In CIN Clinical Trial
Advaxis said that the study is designed to assess the safety and efficacy of ADXS11-001, for the treatment of CIN grade 2/3 commonly known as cervical dysplasia. Reportedly,
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.